Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

9.7 C
Cheshire
Saturday, April 5, 2025

Biofortuna looks to double in size after move to new Deeside HQ

NORTH West biotech company, Biofortuna, has set out plans to double the size of its team after investing in a new headquarters and manufacturing facility in Deeside.

The company, which specialises in developing and manufacturing diagnostic tests for a number of conditions, ranging from lung cancer to COVID, expects to double its headcount from 30 to more than 60 over the next two years as result of its investment.

Backed by Foresight Group, the leading SME investor, Biofortuna has relocated from Brombrough, Wirral, to a purpose-built, facility at Deeside Industrial Park to which has more than doubled capacity and includes a class-leading, humidity-controlled clean room for manufacturing more than 10 million tests per week.

The new jobs will include roles across the whole business including laboratory roles in assay development and manufacturing and commercial roles in project management and sales.

Biofortuna has particular expertise in assay stabilisation; techniques that enable diagnostic tests to be transported and stored at room temperature without the need for expensive and energy inefficient refrigeration and freezing.

Chief Executive Officer Dr Nick Ash said: “This multi-million-pound investment demonstrates our ambition and commitment to become the sector’s leading support specialist, helping our customers to accelerate their diagnostic development programmes from concept to commercialisation.”

Head of Sales Paul Williams added: “This facility will position Biofortuna as one of the leading outsourced providers of genomic services, custom assay development and contract manufacturing.”

David Turner, Director, Foresight Group added “We are delighted to see the progress made by our portfolio company, Biofortuna and the delivery of their growth strategy. 

“The opening of this impressive facility will help position Biofortuna as the leading provider of contract development and manufacturing services to the global in vitro Diagnostic and Point of Care sectors for many years to come”.

Biofortuna was assisted with the property search by Chester based Chartered Surveyors Legat Owen and with the legal contracting and conveyancing by Shoosmiths, Manchester.

spot_imgspot_img

Latest

Planning consent granted in Congleton for McGoff Group

The McGoff Group has received planning permission for a...

Tooltap Launches in Manchester to Bring Equipment Sharing to Local Communities

Manchester-based platform is making it easier for residents to...

Enviro Waste Management Rebrands to Champion Business-Focused Waste Solutions

Enviro Waste Management has revealed a fresh brand identity...

ECB Intraday Liquidity Framework Offers Direction—But Practical Compliance Still a Major Challenge

The European Central Bank’s (ECB) newly established intraday liquidity...
spot_imgspot_img

Newsletter

Don't miss

Planning consent granted in Congleton for McGoff Group

The McGoff Group has received planning permission for a...

ECB Intraday Liquidity Framework Offers Direction—But Practical Compliance Still a Major Challenge

The European Central Bank’s (ECB) newly established intraday liquidity...

£10,000 reward to identify mother of baby found in Kirkham brook

Crimestoppers is offering a reward of up to £10,000...

Batman star Val Kilmer dies, aged 65

Hollywood star Val Kilmer, best known for his roles...

More News

Planning consent granted in Congleton for McGoff Group

The McGoff Group has received planning permission for a new, multi-generational development on Morley Drive in Congleton. The former John Morley site plans were given...

£10,000 reward to identify mother of baby found in Kirkham brook

Crimestoppers is offering a reward of up to £10,000 to aid the investigation into the tragic discovery of a newborn baby. The boy was found...

A New Era in Conveyancing: Kaur Sutherland Pioneers Balanced Practice

In today’s high-pressure legal environment, conveyancing firms are being forced to rethink how they manage rising client demands, maintain business health, and protect staff...